- Home
- Companies
- canada nova scotia
- therapeutic candidate
Show results for
Refine by
Therapeutic Candidate Suppliers Serving Nova Scotia
27 companies found
based inHercules, CALIFORNIA (USA)
Bio-Rad is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for 70 years, our products ...
Reduce Lead Time for Antibody Generation: Assays supporting SARS-CoV-2 vaccine, therapeutic, and diagnostic test development must be robust, scalable, and transferable to laboratories worldwide. They need to be designed and validated rapidly, yet ...
based inSomerset, NEW JERSEY (USA)
As the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world, we conduct all our business responsibly and with integrity. Our ...
To date, over 600 different mAb and mAb fusions and over 160+ different recombinant proteins have been produced using the GPEx system, with 160+ clinical trials utilizing therapeutic candidates developed using GPEx ...
based inSan Diego, CALIFORNIA (USA)
Vala Sciences helps researchers achieve an unrivaled in vitro understanding of how human cells respond to drug compounds. Vala is committed to providing expert services to pharmaceutical developers and researchers to help overcome the persistent ...
based ins-Hertogenbosch, NETHERLANDS
We make up a top-class and diverse team of experts, with the right combination of knowledge and expertise to jointly tackle the data analysis and software engineering challenges related to the field of immunomics. Together with our scientific and ...
Antibody display campaigns can generate numerous datasets. The analysis of this data is slow, resource-intensive, and picking candidates often relies on making decisions on a ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
Monoclonal antibodies (mAbs) are powerful therapeutic tools. These glycoproteins, belonging to the immunoglobulin (Ig) family, are utilized by the immune system to identify and neutralize foreign organisms or antigens. Ig’s are classified in five ...
based inCranbury, NEW JERSEY (USA)
Advancing an integrated pipeline of genetic therapies that correct the root cause of complex and rare life-threatening childhood disorders. Our mission is to develop first-in-class and best-in-class, curative gene therapies for patients with ...
The LVV platform is ideal for modifying hematopoietic stem cells (HSCs) to address disorders affecting the bone marrow. The LVV transduction process occurs ex vivo (outside the body), which ensures that the gene has been properly ...
based inAnn Arbor, MICHIGAN (USA)
BlueWillow Biologics is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines using its patented nanoemulsion platform. The platform, originally discovered at the University of ...
Herpes simplex virus-2 (HSV-2) is the leading cause of genital herpes, a sexually transmitted disease affecting over 500 million people worldwide. BlueWillow’s intranasal nanoemulsion (NE) vaccine is uniquely suited to offer protection against ...
based inJupiter, FLORIDA (USA)
Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and ...
We are building an active pipeline of products for human health by applying our proprietary and patented C1 technology to develop vaccines and antibodies for infectious and other diseases. Vaccine Development: The C1 platform is ready for full ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
Advances in the field of immuno-oncology have led to new and better treatment outcomes for a range of cancers, and particularly, blood cancers. However, even with the advent of checkpoint inhibitors as immunotherapies for solid tumors, significant ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
based inHamburg, GERMANY
Revvity Gene Delivery (formerly SIRION Biotech) supports your cell and gene therapy development process ̶ offering solutions for early R&D all the way to clinical applications, with easy transfer of processes and assays into GMP production. ...
In the discovery of oncology therapeutics, Antibody-drug conjugates (ADCs) are rapidly gaining momentum, with hundreds of candidates advancing through clinical development. Whether your priority lies in assessing ...
based inCambridge, UNITED KINGDOM
GW is the global leader in developing cannabinoid-based medicines. GW has been researching cannabinoids since 1998 and has established a world leading position in the development of plant-derived cannabinoid therapeutics. GW has established a world ...
based inNew York, NEW YORK (USA)
NuBiyota is a microbiome therapeutics company focused on the development of novel microbiota-based drugs to restore crucial gut equilibrium. An imbalance in this crucial ecosystem is associated with infections, chronic disease and even neurological ...
based inLeiden, NETHERLANDS
A leading pioneer in leveraging iPSC innovation for drug discovery. The catalyst with the requisite iPSC know-how and experience to empower innovators in drug discovery to advance their science relentlessly, consistently and efficiently. For the ...
Human-induced pluripotent stem cell (iPSC) derived atrial cardiomyocytes are a powerful tool to improve in vitro testing of new treatments for atrial arrhythmias. Our team can manufacture atrial cardiomyocytes at the scale needed from the iPSC that ...
based inNaples, FLORIDA (USA)
Enveric Biosciences is leveraging its discovery engine and intellectual property portfolio to identify and build the next generation of psychedelic and cannabinoid medicines for the mind and body. By harnessing the power of synthetic biology and ...
based inNewcastle Upon Tyne, UNITED KINGDOM
Newcells offers expert disease modelling services using best in class in vitro platforms and supports drug development by providing robust data for regulatory submissions and the critical decision-making process. Newcells mission is to de-risk the ...
In vitro assessment of Fibroblast-to-Myofibroblast transition (FMT). Newcells offers a fast and reliable FMT assay service to evaluate the efficacy of anti-fibrotic compounds using high-content imaging. This customisable, high-throughput assay is ...
based inLeiden, NETHERLANDS
We are a global leader in human 3D disease modeling using our organ-on-a-chip platform, the OrganoPlate. We work with top pharmaceutical and biotech companies to develop novel therapies against unsolved diseases. Our human tissue & disease modeling ...
Profiling and screening of your compounds with a high throughput barrier integrity assay on our established Caco-2 intestinal model. OrganoServices are available for multiple assays to allow compound profiling and/or screening in human-relevant, ...
based inSunnyvale, CALIFORNIA (USA)
We are developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases. Our Mission: To improve the lives of patients with cardiovascular and pulmonary diseases through the development of ...
based inBrisbane City, AUSTRALIA
Microba’s precise microbiome analysis is built on the expertise of our innovative team at the leading edge of microbiome science. Our approach to microbiome analysis is enabling new discoveries and advancing the understanding of the microbiome in ...
Developing novel therapeutics from the human microbiome; The uncultured portion of the human gut microbiome, which is the majority of microbial species, represents untapped therapeutic opportunity. Microba has established a platform for drug ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients. Our TCR T-cell therapies have advantages over other immune ...